161 related articles for article (PubMed ID: 38026930)
1. Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov.
Dai Z; Li N; Wang J; Tan C; Zhang Y; Liu L
Front Pharmacol; 2023; 14():1212813. PubMed ID: 38026930
[No Abstract] [Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database.
Peng H; Chen L; Chen YP; Li WF; Tang LL; Lin AH; Sun Y; Ma J
PLoS One; 2018; 13(5):e0196730. PubMed ID: 29718970
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of immunotherapy trials for nasopharyngeal carcinoma over a 15-year period.
Huang H; Yao Y; Deng X; Weng H; Chen Z; Yu L; Wang Z; Fang X; Hong H; Huang H; Lin T
Front Immunol; 2023; 14():1195659. PubMed ID: 37622113
[TBL] [Abstract][Full Text] [Related]
5. Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma.
Cao Y; Chan KI; Xiao G; Chen Y; Qiu X; Hao H; Mak SC; Lin T
BMC Cancer; 2019 Oct; 19(1):1022. PubMed ID: 31664962
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials.
Xu K; De Ravin E; Suresh N; Brody RM; Rajasekaran K
World J Otorhinolaryngol Head Neck Surg; 2023 Jun; 9(2):174-182. PubMed ID: 37383331
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.
Wang BC; Cao RB; Fu C; Chen WB; Li PD; Lin GH; Qian XJ; Li YT; Liu Q
Oral Oncol; 2020 May; 104():104640. PubMed ID: 32182550
[TBL] [Abstract][Full Text] [Related]
10. The fate of prospective spine studies registered on www.ClinicalTrials.gov.
Ohnmeiss DD
Spine J; 2015 Mar; 15(3):487-91. PubMed ID: 25315132
[TBL] [Abstract][Full Text] [Related]
11. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.
Chan OS; Kowanetz M; Ng WT; Koeppen H; Chan LK; Yeung RM; Wu H; Amler L; Mancao C
Oral Oncol; 2017 Apr; 67():52-60. PubMed ID: 28351581
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.
Adkins DR; Haddad RI
Cancer Treat Rev; 2022 Sep; 109():102428. PubMed ID: 35753157
[TBL] [Abstract][Full Text] [Related]
13. Clinical Trials Focusing on Drug Control and Prevention of Ventilator-Associated Pneumonia: A Comprehensive Analysis of Trials Registered on ClinicalTrials.gov.
Chen L; Su Y; Quan L; Zhang Y; Du L
Front Pharmacol; 2018; 9():1574. PubMed ID: 30863312
[No Abstract] [Full Text] [Related]
14. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
15. Overview of Clinical Trials on Type 2 Diabetes Mellitus: A Comprehensive Analysis of the ClinicalTrials.gov Database.
Long J; Liang R; Zheng Q; Yuan G; Xin Z; Chen X; Lai F; Liu Y
Diabetes Metab Syndr Obes; 2021; 14():367-377. PubMed ID: 33531823
[TBL] [Abstract][Full Text] [Related]
16. PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes.
Zhou Y; Miao J; Wu H; Tang H; Kuang J; Zhou X; Peng Y; Hu D; Shi D; Deng W; Cao X; Zhao C; Xie C
Oncotarget; 2017 Aug; 8(31):51210-51223. PubMed ID: 28881642
[TBL] [Abstract][Full Text] [Related]
17. Registered Trials on Artificial Intelligence Conducted in Emergency Department and Intensive Care Unit: A Cross-Sectional Study on ClinicalTrials.gov.
Liu G; Li N; Chen L; Yang Y; Zhang Y
Front Med (Lausanne); 2021; 8():634197. PubMed ID: 33842500
[No Abstract] [Full Text] [Related]
18. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
20. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi YR; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Liu Z; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Feng H; Yao S; Keegan P; Xu RH
Nat Med; 2021 Sep; 27(9):1536-1543. PubMed ID: 34341578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
